Low-dose radiation therapy (LDRT) for osteoarthritis uses a total dose of approximately 3 Gy, delivered as 6 fractions of 0.5 Gy each, two to three times per week. This is roughly 13 to 27 times lower than doses used to treat cancer. The estimated additional secondary malignancy risk is approximately 0.06 percent. No published case reports of secondary malignancy from LDRT for osteoarthritis exist. There are no published data demonstrating a negative impact on subsequent joint replacement surgery.
LDRT for osteoarthritis: 3 Gy total (full course). Radiation therapy for breast cancer: 40 to 50 Gy. Radiation therapy for prostate cancer: 70 to 80 Gy. Radiation therapy for head and neck cancer: 66 to 70 Gy. The treatment dose used for osteoarthritis pain relief is a small fraction of what cancer patients receive — the comparison makes clear this is a fundamentally different scale of exposure.
The 2026 ARS Appropriate Use Criteria estimates an additional secondary malignancy risk of approximately 0.06 percent (6 in 10,000 patients) when approximately 2 percent of total body red bone marrow is in the radiation field at a total dose of 3 Gy. This is a modeled estimate based on linear no-threshold radiation risk models — not a figure directly observed in LDRT patients. The femoral and humeral heads (hips and shoulders) contain roughly 1 to 2 percent of total body red bone marrow; distal joints such as knees, wrists, hands, and feet contain far less active marrow, making the marrow-irradiated fraction substantially lower for those treatments.
Despite decades of clinical use in Europe — with large published series from Germany, the Netherlands, Belgium, Spain, and Switzerland covering thousands of treated joints — there are no published case reports of secondary malignancy attributable to LDRT treatment for osteoarthritis as of the 2026 ARS AUC publication. The absence of case reports is reassuring; it does not mean the risk is zero, but it means any risk has not been large enough to produce observable cases in the published record.
Radiation-induced solid tumors typically appear 10 to 60 years after exposure. Radiation-induced leukemias typically appear 5 to 10 years after exposure. This long latency window is precisely why the ARS AUC recommends against LDRT in patients under age 40. For a 75-year-old, a risk that materializes in 10 to 60 years carries different practical weight than the same risk for a 35-year-old whose entire active life falls within that window. Age is built into the candidacy criteria because the risk calculus is genuinely different.
LDRT uses an external beam of X-rays directed at the joint from outside the body. No radioactive material is placed in the body, and no radioactivity remains after treatment. Patients can return to all normal activities — including being around children, pregnant people, and pets — immediately after every session. There is no isolation period.
The ARS AUC notes no published data demonstrating a negative impact of LDRT on subsequent surgical procedures, including total joint replacement. This directly addresses a common patient concern about "burning bridges." The available evidence does not support that concern. If this is a specific worry, discuss it with the radiation oncologist at consultation.
Retrospective data on younger women who received low-dose shoulder radiotherapy suggest no higher breast cancer risk than matched control populations. The shoulder is anatomically close to breast tissue, making this a reasonable concern. Available retrospective evidence is reassuring, though prospective long-term data in this specific population remain limited.
No dose of ionizing radiation is considered entirely without risk by the established radiation protection framework. The 0.06 percent estimate is model-based, not directly observed. Long-term surveillance studies with contemporary dosimetry and extended follow-up are still accumulating. The ARS AUC represents the current expert synthesis of available evidence. A radiation oncologist experienced in LDRT for osteoarthritis can help weigh these considerations against your specific clinical situation, age, joint involved, and treatment history.
Related pages: Am I a candidate? | Side effects and what to expect | Clinical evidence
Medically reviewed by: Robert Warren Floyd, M.D., Ph.D. — Resident Physician, Radiation Oncology, The University of Texas MD Anderson Cancer Center. Last reviewed: August 2, 2026. Independent personal project — not affiliated with or endorsed by MD Anderson Cancer Center. Funding & independence disclosure.